Swetha Kambhampati, MD, of the City of Hope, speaks with Chadi Nabhan, MD, MBA, FACP, about her presentation during the 2023 American Society of Clinical Oncology Annual Meeting.
Dr. Kambhampati presented her research on real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma during an oral abstract session at the annual meeting.
“This is the largest real-world study to date looking at safety and efficacy of brexucabtagene autoleucel,” Dr. Kambhampati said.
The real-world study included a “heavily pretreated high-risk” population of patients with a median age of around 67 years, she said.
“These are patients getting it in our day-to-day practices, so it included patients with high-risk disease features,” Dr. Kambhampati said.
The study, which included 380 patients with a median follow-up of 12 months, showed an overall response rate of 90%, with a complete response rate of 78%. The real-world results were “very comparable” to those seen in the ZUMA-2 trial, Dr. Kambhampati said.
She also spoke about how the real-world safety findings compared with those seen in the ZUMA-2 study, she said.
“The safety profile appeared to be fairly comparable—at least in the [cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome], and infection rates—to that reported in ZUMA-2 in this real-world patient population,” Dr. Kambhampati said.
Overall, the findings suggest that the real-world outcomes are “consistent regardless” of prior exposure to a Bruton’s tyrosine kinase inhibitor, bendamustine, or autologous hematopoietic stem cell transplantation, according to Dr. Kambhampati and colleagues.